small molecule glp 1 agonist PDB-101: of the Month: GLP-1 Receptor Agonists Drug Hunter's 2023 Patent Review

Furthermore, earlier work indicated that this effect may entail a local upregulation of brain IL-6 in the hypothalamus, by both amylin and GLP-1 [20]

Additionally, combination treatment was superior to treatment with liraglutide and showed a trend to towards superiority to KBP-089 alone (Fig

While their metabolic benefits are well-established, their potential effects on vestibular function remain unexplored

[DOI] [PubMed] [Google Scholar] [174].Teva Pharmaceutical Industries Ltd, TEVA SETTLES PATENT LITIGATION WITH ASTRAZENECA ALLOWING TEVA TO COMMERCIALIZE ITS GENERIC VERSION OF BYETTA (EXENATIDE INJECTION) IN THE UNITED STATES, 2016

A recombinant human glucagon-like peptide (GLP)-1albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis

10.1161/CIRCULATIONAHA.111.041418 174 ShahZ.PinedaC.KampfrathT.MaiseyeuA.YingZ.RacomaI.et al (2011b)